Brief: Actinium Pharmaceuticals Announces Dr. Sergio Giralt To Discuss Positive Results From The Pivotal Phase 3 Sierra Trial Of Iomab-B Via Kol Webinar
27/02/2023 13:58
Feb 27 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM PHARMACEUTICALS ANNOUNCES DR. SERGIO GIRALT TO
DISCUSS
POSITIVE RESULTS FROM THE PIVOTAL PHASE 3 SIERRA TRIAL OF
IOMAB-B VIA KOL WEBINAR
* INTENDS TO FILE A BLA FOR IOMAB-B IN 2H:2023 FOLLOWING
POSITIVE
SIERRA TRIAL RESULTS
* REITERATES CURRENT CASH AND CASH EQUIVALENTS OF
APPROXIMATELY
$100 MILLION ARE PROJECTED TO FUND OPERATIONS THROUGH 2025
Source text for Eikon: ID:nPn1YqqdGa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities